Clinically, PARP inhibitors (PARPi) are used to treat certain cancers through synthetic lethality, for example, by exploiting genetic vulnerabilities present in BRCA1/2-deficient ovarian, breast, and prostate cancer [2]. This evidence concerns the gene PARP1 and cancer.